Overall, LPAR6 expression is downregulated in breast cancer, and this is correlated with poor clinicopathological features, including pathological grades and clinical stages, which indicates that LPAR6 acts as a suppressor in breast cancer. Here, LPAR6 is linked to breast carcinoma.